1. Home
  2. WGS vs WSBCO Comparison

WGS vs WSBCO Comparison

Compare WGS & WSBCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WGS
  • WSBCO
  • Stock Information
  • Founded
  • WGS 2017
  • WSBCO N/A
  • Country
  • WGS United States
  • WSBCO United States
  • Employees
  • WGS N/A
  • WSBCO N/A
  • Industry
  • WGS Retail: Computer Software & Peripheral Equipment
  • WSBCO Major Banks
  • Sector
  • WGS Technology
  • WSBCO Finance
  • Exchange
  • WGS Nasdaq
  • WSBCO Nasdaq
  • Market Cap
  • WGS 2.4B
  • WSBCO 2.5B
  • IPO Year
  • WGS N/A
  • WSBCO N/A
  • Fundamental
  • Price
  • WGS $139.62
  • WSBCO $25.45
  • Analyst Decision
  • WGS Strong Buy
  • WSBCO
  • Analyst Count
  • WGS 8
  • WSBCO 0
  • Target Price
  • WGS $130.63
  • WSBCO N/A
  • AVG Volume (30 Days)
  • WGS 591.1K
  • WSBCO N/A
  • Earning Date
  • WGS 10-28-2025
  • WSBCO N/A
  • Dividend Yield
  • WGS N/A
  • WSBCO N/A
  • EPS Growth
  • WGS N/A
  • WSBCO N/A
  • EPS
  • WGS 0.07
  • WSBCO N/A
  • Revenue
  • WGS $402,190,000.00
  • WSBCO N/A
  • Revenue This Year
  • WGS $39.54
  • WSBCO N/A
  • Revenue Next Year
  • WGS $22.50
  • WSBCO N/A
  • P/E Ratio
  • WGS $1,886.07
  • WSBCO N/A
  • Revenue Growth
  • WGS 50.50
  • WSBCO N/A
  • 52 Week Low
  • WGS $55.17
  • WSBCO N/A
  • 52 Week High
  • WGS $146.00
  • WSBCO N/A
  • Technical
  • Relative Strength Index (RSI)
  • WGS 64.99
  • WSBCO N/A
  • Support Level
  • WGS $133.00
  • WSBCO N/A
  • Resistance Level
  • WGS $142.27
  • WSBCO N/A
  • Average True Range (ATR)
  • WGS 9.13
  • WSBCO 0.00
  • MACD
  • WGS 1.23
  • WSBCO 0.00
  • Stochastic Oscillator
  • WGS 83.67
  • WSBCO 0.00

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.

Share on Social Networks: